Roche Holding Ag Stock News

In the YOSEMITE and RHINE studies in diabetic macular edema, at least 60% of eligible Vabysmo patients could extend treatment to every four months at two…

In the YOSEMITE and RHINE studies in diabetic macular edema, at least 60% of eligible Vabysmo patients could extend treatment to every four months at two years, compared to 50% at year one Almost 80% of eligible Vabysmo patients could extend treatment to every three months or longer in both studies In the Archway study in neovascular age-related macular degeneration, 95% of Susvimo patients maintained a six-month treatment schedule at two years Basel, 11 February 2022 - Roche ((SIX: RO, ROG, OTCQX: RHHBY ) today announced that new two-year data from its phase III studies of Vabysmo™ (faricimab) and Susvimo™ (previously called Port Delivery System with ranibizumab) will be presented at Angiogenesis, Exudation and Degeneration 2022 on 12 February. These longer-term results from the Vabysmo YOSEMITE and RHINE studies in diabetic macular edema (DME) and the Susvimo Archway study in neovascular or "wet" age-related macular degeneration (nAMD) further reinforce the potential to allow for longer time between treatments and fewer eye injections for people with these conditions, while still achieving and maintaining vision gains seen with previous standard-of-care injections.

OSLO, Norway, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Nykode Therapeutics AS (Euronext Growth (Oslo): NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of vaccines and novel immunotherapies, today announced the completion of patient enrollment in the Phase 2 study of VB10.16, Nykode’s lead cancer vaccine candidate, in combination with Roche’s checkpoint inhibitor atezolizumab for the treatment of advanced cervical cancer. VB10.16 is a potentially first-in-class off-the-shelf therapeutic HPV16 cancer vaccine designed to induce strong HPV16 specific T cell responses for the treatment of HPV16-positive cancers.

Specialty Pharmaceutical Market 2022 Covid 19 Impact on Top countries data Industry Trends, Share, Size, Demand, Growth Opportunities, Industry Revenue, Future and Business Analysis by Forecast New York, NY -- ( SBWIRE ) -- 02/09/2022 -- Specialty Pharmaceutical Market 2022-2028 A New Market Study, Titled "Specialty Pharmaceutical Market Upcoming Trends, Growth Drivers and Challenges" has been featured on fusionmarketresearch. Description This global study of the Specialty Pharmaceutical Market offers an overview of the existing market trends, drivers, restrictions, and metrics and also offers a viewpoint for important segments. The report also tracks product and services demand growth forecasts for the market. There is also to the study approach a detailed segmental review. A regional study of the global Specialty Pharmaceutical industry is also carried out in North America, Latin America, Asia-Pacific, Europe, and the Near East & Africa. The report mentions growth parameters in the regional markets along with major players dominating the regional growth.

Roche suggested that many investors were underestimating the potential ramifications of the Russia-Ukraine crisis.

SHANE ROCHE still has belief in his team to break their losing sequence despite their poor start to Division 4 of the Allianz Football League.

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland February 8 , 202 2 Idorsia Ltd (SIX: IDIA) today announced its financial results for 2021. Business highlights QUVIVIQ (daridorexant) 25 mg and 50 mg approved by the US Food and Drug Administration (FDA) for the treatment of adults with insomnia Marketing Authorization Application for daridorexant for the treatment of adults with insomnia under review with European Medicines Agency, Swissmedic, and Health Canada PIVLAZ (clazosentan) 150 mg approved in Japan for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage Commercial organizations established in key markets in Europe and scaled-up in US and Japan in preparation for first product launches Phase 3 study with selatogrel for the treatment of acute myocardial infarction initiated Results from CARE study with cenerimod for systemic lupus erythematosus inform the decision to advance to Phase 3 Results for MODIFY study with lucerastat for Fabry disease show potential effect on organ function to be further investigated in the ongoing open-label extension Phase 2 proof-of-concept study with SO1RA for binge eating disorder completed recruitment Ponesimod to treat relapsing forms of multiple sclerosis approved in US and EU, resulting in Idorsia receiving first income from the revenue-sharing agreement with Janssen Pharmaceuticals Financial highlights Maintained strong balance sheet by successfully securing a CHF 600 m convertible bond US GAAP operating expenses 2021 at CHF 648 million Non-GAAP operating expenses 2021 at CHF 612 million Guidance for 202 2 : Net revenue around CHF 145 million US GAAP operating expenses around CHF 975 million and non-GAAP operating expenses around CHF 920 million leading to US GAAP operating loss of around CHF 840 million and non-GAAP operating loss of around CHF 785 million unforeseen events excluded Profitability target : The company is committed to become profitable and expects to reach this goal in 2025 with sales above CHF 1 billion.

Roche (RHHBF) CEO Severin Schwan 2021 remuneration increased to CHF11.49M, compared to CHF11.03M in 2020.Meanwhile, the total compensation for Novartis (NVS) CEO Vasant Narasimhan

Callable Multi Barrier Reverse Convertible auf BioNTech, Johnson & Johnson, Merck, Moderna, Pfizer / Idorsia, Lonza, Novartis, Roche, Zur Rose Group AG

David Roche, president and global strategist at Independent Strategy, discusses the bond market and his outlook for the global economy.

Investors should short government bonds with higher interest rates now being "inevitable" around the world, a strategist has advised.

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big pharma earnings. The sector came back up in the final session for a firm finish. Merck & Co., Inc. (NASDAQ: MRK ) issued mixed 2022 guidance and Swiss pharma giant Roche Holding AG (OTC: RHHBY ) warned of slowing growth in 2022. Biogen, Inc. (NASDAQ: BIIB ) shares moved to the downside as they reacted to weak guidance and not-so-promising commentary about sales of the company''s Alzheimer''s drug Aduhelm. On the regulatory front, the Food and Drug Administration approved Viatris Inc.''s (NASDAQ: VTRS ) generic version of AbbVie, Inc.''s (NYSE: ABBV ) dry eye disease drug Restasis. Sanofi (NASDAQ: SNY ) received the nod for its medication Enjaymo, targeting a rare blood disorder known as cold agglutinin disease. LogicBio Therapeutics, Inc. (NASDAQ: LOGC ) shares shed over 50% during the week after the FDA imposed a clinical hold on a Phase 1/2 study of its AAV-delivered genomic editing therapy LB-001 to treat a rate metabolic disorder in children.

Big pharma reporting season was muted, with the quarterly results and guidance coming in mixed. Merck & Co Inc (NYSE: MRK ) shares pulled back despite the company reporting this week above-consensus results, with the negative reaction reflecting investors concerns over the sustainability of its oral COVID-19 pill revenues. Roche Holding AG (OTC: RHHBY ) also pulled back as the Swiss pharma giant flagged slowing COVID testing revenues. What Happened: Against this backdrop, money manager Cathie Wood''s Ark Invest sold a trio of biopharma stocks on Friday, according to daily trade information released by the fund. The ARK Genomic Revolution ETF (BATS: Full story available on Benzinga.com